1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine is a chemical compound that is a potent and selective inhibitor of the enzyme **protein kinase C (PKC)**.
**Here's a breakdown of the compound and its importance in research:**
**Structure and Properties:**
* **Chemical Formula:** C22H23N3O
* **Molecular Weight:** 345.44 g/mol
* **Appearance:** A white to off-white solid
* **Key Features:** It has a quinoline ring system with a methyl group at the 1-position and a morpholine-containing phenyl group attached at the 2-position.
**Why is it important for research?**
* **Protein Kinase C (PKC) Inhibition:** PKC is a family of enzymes that play a crucial role in many cellular processes, including cell growth, differentiation, and apoptosis. Dysregulation of PKC is implicated in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. 1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine's ability to inhibit PKC makes it a valuable tool for studying the roles of PKC in these diseases.
* **Drug Development:** This compound's potent and selective inhibition of PKC has sparked interest in its potential as a lead compound for developing new drugs to treat PKC-related diseases. Researchers are investigating its efficacy and safety in various preclinical models.
* **Understanding PKC Function:** By studying the effects of 1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine on cells and tissues, researchers can gain deeper insights into how PKC works and its role in various biological pathways.
**Research Applications:**
* **Cancer Research:** Investigating the compound's potential to inhibit the growth and proliferation of cancer cells.
* **Cardiovascular Research:** Exploring its potential to prevent or treat cardiovascular diseases by modulating PKC activity.
* **Neurological Research:** Examining its effects on neuronal function and potential applications in treating neurological disorders.
* **Inflammation Research:** Investigating its ability to reduce inflammation by influencing PKC activity.
**In summary, 1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine is a valuable research tool due to its potent and selective inhibition of PKC. It holds promise for drug development and for furthering our understanding of the complex role of PKC in various biological processes and diseases.**
| ID Source | ID |
|---|---|
| PubMed CID | 3241706 |
| CHEMBL ID | 3190439 |
| CHEBI ID | 109019 |
| Synonym |
|---|
| HMS1488K22 |
| CHEMDIV3_005522 |
| n-[(2z)-1-methylquinolin-2(1h)-ylidene]-n-(4-morpholin-4-ylphenyl)amine |
| smr000020059 |
| MLS000085321 , |
| IDI1_023432 |
| CHEBI:109019 |
| BRD-K49568696-001-01-1 |
| AKOS001687055 |
| 1-methyl-n-(4-morpholin-4-ylphenyl)quinolin-2-imine |
| HMS2172L06 |
| HMS3314C17 |
| REGID_FOR_CID_3241706 |
| CHEMBL3190439 |
| 1-methyl-n-[4-(4-morpholinyl)phenyl]-2-quinolinimine |
| Q27188009 |
| sr-01000085715 |
| SR-01000085715-1 |
| Class | Description |
|---|---|
| morpholines | Any compound containing morpholine as part of its structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.8913 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 89.1251 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| TDP1 protein | Homo sapiens (human) | Potency | 26.1011 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 95.2400 | 0.1800 | 13.5574 | 39.8107 | AID911 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 100.0000 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 2.5119 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | Potency | 95.2400 | 0.1800 | 3.9550 | 7.7300 | AID911 |
| Leukotriene B4 receptor 2 | Homo sapiens (human) | Potency | 95.2400 | 0.1800 | 3.9550 | 7.7300 | AID911 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleotide binding | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| leukotriene receptor activity | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| G protein-coupled peptide receptor activity | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| leukotriene B4 receptor activity | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| leukotriene receptor activity | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| leukotriene B4 receptor activity | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| G protein-coupled peptide receptor activity | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| nucleoplasm | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||